NASDAQ
Apellis Pharmaceuticals, Inc. (APLS) has had 180 insider transactions recently, with net insider activity of -$7.08M (net selling). The most active insider is Deschatelets Pascal (Officer: chief scientific officer).
Total Transactions
180
36 buys /144 sells
Shares Acquired
1,411,957
Transactions: 36•Avg: 39,221.03
Shares Disposed
8,493,989
Transactions: 144•Avg: 58,986.03
Net Activity
-7,082,032
Net Selling•Ratio: 25%
Q2 2026(Current) | 1,411,957 | 8,493,989 | -7,082,032 | 25.00% |
Q1 2026 | 780,819 | 193,154 | +587,665 | 100.00% |
Q4 2025 | 10,000 | 69,929 | -59,929 | 14.29% |
Q3 2025 | 320,638 | 622,414 | -301,776 | 38.10% |
Q2 2025 | 1,025,012 | 22,567 | +1,002,445 | 533.33% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q2 2026
Acquired vs Disposed Shares
Net Distribution: 7,082,032 shares•Acquired/Disposed Ratio: 25%
Net Activity | |||||
|---|---|---|---|---|---|
DP Deschatelets Pascal | Officer: chief scientific officer | 15 | 90,040 | 1,792,058 | -1,702,018 |
STE Sullivan Timothy Eugene | Officer: chief financial officer | 15 | 159,080 | 807,022 | -647,942 |
MA Machiels Alec | Director | 11 | 0 | 395,844 | -395,844 |
NN Nicholson Nur | Officer: chief technical officer | 11 | 133,364 | 483,680 | -350,316 |
CG Chan Gerald | Director | 11 | 0 | 271,510 | -271,510 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2026-05-14 | Director | Sale | 3,544 | $0 | $0 | - | |
2026-05-14 | Director | Sale | 14,684 | $25.12 | $368,862.08 | - | |
2026-05-14 | Director | Sale | 27,600 | $30.62 | $845,112 | - | |
2026-05-14 | Director | Sale | 11,199 | $31.91 | $357,360.09 | - | |
2026-05-14 | Director | Sale | 8,554 | $47.28 | $404,433.12 | - |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
DAS Dunlop A. Sinclair | Director | May 14, 2026 | |
DAS Dunlop A. Sinclair | Director | May 14, 2026 | |
DAS Dunlop A. Sinclair | Director | May 14, 2026 | |
DAS Dunlop A. Sinclair | Director | May 14, 2026 | |
DAS Dunlop A. Sinclair | Director | May 14, 2026 |
Net change in shares shown on right
No price data available for this timeframe.